Endeavor Vision, a Swiss venture firm that invests internationally, has raised $375 million for its second fund committed to commercial-stage healthcare-technology companies.

Endeavor, whose investment teams are based in Geneva and Minneapolis, set out to raise $400 million for Endeavor Medtech Growth II LP in late 2019, but didn’t manage to reach its goal, stated Bernard Vogel, co-founder and managing partner with the firm. The pandemic made it challenging to travel and maintain relationships with new investors, he stated, adding that previous investors supplied roughly 55% of the capital in this new fund. 

Endeavour formed in 2000 and previously was a generalist firm investing in life sciences and technology. Early last decade, the team observed that many medical-technology venture investors were choosing early-stage companies but that less specialized in growth financing for commercial-stage businesses.